

## AMENDMENTS TO THE CLAIMS

1. (Previously amended) A combination product for the treatment of cancer in a mammal, said combination product comprising: an antisense oligonucleotide of between 7 and 100 nucleotides in length comprising at least 7 consecutive nucleotides complementary to a mammalian ribonucleotide reductase R2 subunit mRNA and one or more immunotherapeutic agents.
2. (Original) The combination product according to claim 1, wherein said mammalian ribonucleotide reductase R2 subunit mRNA is a human ribonucleotide reductase R2 subunit mRNA.
3. (Original) The combination product according to claim 2, wherein said human ribonucleotide reductase R2 subunit mRNA has a sequence as set forth in SEQ ID NO:105.
4. (Original) The combination product according to claim 2, wherein said antisense oligonucleotide comprises at least 7 consecutive nucleotides of the sequence as set forth in any one of SEQ ID NOs:1 and 4-104.
5. (Original) The combination product according to claim 2, wherein said antisense oligonucleotide comprises at least 7 consecutive nucleotides of the sequence as set forth in SEQ ID NO:1.
6. (Previously amended) The combination product according to claim 1, wherein said antisense oligonucleotide comprises one or more phosphorothioate internucleotide linkages.

7. (Previously amended) The combination product according to claim 1, wherein said cancer is an advanced cancer.
8. (Previously amended) The combination product according to claim 1, wherein said cancer is a metastatic cancer.
9. (Previously amended) The combination product according to claim 1, wherein said treatment is a first-line systemic therapy.
10. (Previously amended) The combination product according to claim 1, wherein said one or more immunotherapeutic agents are non-specific immunotherapeutic agents.
11. (Previously amended) The combination product according to claim 1, wherein said one or more immunotherapeutic agents are specific immunotherapeutic agents.
12. (Previously amended) The combination product according to claim 1, wherein said one or more immunotherapeutic agents are a cytokine, a non-cytokine adjuvant, a monoclonal antibody or a cancer vaccine.
13. (Previously amended) The combination product according to claim 1, wherein said one or more immunotherapeutic agents are a cytokine or a non-cytokine adjuvant.
14. (Previously amended) The combination product according to claim 1, wherein said one or more immunotherapeutic agents are one or more cytokines.
15. (Previously amended) The combination product according to claim 1, wherein said

combination product further comprises one or more chemotherapeutic agents.

16. (Previously amended) The combination product according to claim 1, wherein said cancer is a solid cancer.
17. (Previously amended) The combination product according to claim 1, wherein said mammal is a human.
18. (Currently amended) A method of treating cancer in a mammal comprising administering to said mammal ~~a combination product comprising:~~
  - (a) an antisense oligonucleotide of between 7 and 100 nucleotides in length comprising at least 7 consecutive nucleotides complementary to a mammalian ribonucleotide reductase R2 subunit mRNA, and
  - (b) one or more immunotherapeutic agents.
19. (Original) The method according to claim 18, wherein said mammalian ribonucleotide reductase R2 subunit mRNA is a human ribonucleotide reductase R2 subunit mRNA.
20. (Previously amended) The method according to claim 19, wherein said human ribonucleotide reductase R2 subunit mRNA has a sequence as set forth in SEQ ID NO:105.
21. (Original) The method according to claim 19, wherein said antisense oligonucleotide comprises at least 7 consecutive nucleotides of the sequence as set forth in any one of SEQ ID NOs:1 and 4-104.
22. (Original) The method according to according to claim 19, wherein said antisense

oligonucleotide comprises at least 7 consecutive nucleotides of the sequence as set forth in SEQ ID NO:1.

23. (Previously amended) The method according to claim 18, wherein said antisense oligonucleotide comprises one or more phosphorothioate internucleotide linkages.

24. (Previously amended) The method according to claim 18, wherein said cancer is an advanced cancer.

25. (Previously amended) The method according to claim 18, wherein said cancer is a metastatic cancer.

26. (Currently amended) The method according to claim 18, wherein said ~~combination product~~method is administered to said mammal ~~as a~~ first-line systemic therapy.

27. (Previously amended) The method according to claim 18, wherein said one or more immunotherapeutic agents are non-specific immunotherapeutic agents.

28. (Previously amended) The method according to claim 18, wherein said one or more immunotherapeutic agents are specific immunotherapeutic agents.

29. (Previously amended) The method according to claim 18, wherein said one or more immunotherapeutic agents are a cytokine, a non-cytokine adjuvant, a monoclonal antibody or a cancer vaccine.

30. (Previously amended) The method according to claim 18, wherein said one or more immunotherapeutic agents are a cytokine or a non-cytokine adjuvant.

31. (Previously amended) The method according to claim 18, wherein said one or more immunotherapeutic agents are one or more cytokines.
32. (Currently amended) The method according to claim 18, wherein said ~~combination product~~method further comprises administering one or more chemotherapeutic agents to said mammal.
33. (Previously amended) The method according to claim 18, wherein said cancer is a solid cancer.
34. (Previously amended) The method according to claim 18, wherein said mammal is a human.
- 35-51. (Cancelled)
52. (Original) A pharmaceutical kit comprising a combination product for the treatment of cancer, said combination product comprising:
- (a) an antisense oligonucleotide of between 7 and 100 nucleotides in length comprising at least 7 consecutive nucleotides complementary to a mammalian ribonucleotide reductase R2 subunit mRNA, and
  - (b) one or more immunotherapeutic agents.
53. (Previously amended) A combination product for the treatment of renal cancer in a subject, said combination product comprising: an antisense oligonucleotide of between 7 and 100 nucleotides in length comprising at least 7 consecutive nucleotides complementary to SEQ ID NO:1 and one or more cytokines.

54. (Previously amended) The combination product according to claim 53, wherein said one or more cytokines are interferon alpha or interleukin-2.
55. (Previously amended) The combination product according to claim 53, wherein said treatment is a first-line systemic therapy.